Glax­o­SmithK­line backs a pre­clin­i­cal ac­ne treat­ment from Eli­go Bio­science that us­es CRISPR to kill bac­te­ria

Rough­ly three and a half years since bag­ging a $20 mil­lion fi­nanc­ing round to de­vel­op its CRISPR-based mi­cro­bio­me mod­u­la­tion plat­form, Eli­go Bio­science has made …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.